Navigation Links
PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
Date:4/10/2008

BOSTON, April 10 /PRNewswire-FirstCall/ -- Senior experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will discuss best practices for successful partnerships at the 17th Annual Partnerships with CROs conference, to be held April 14-16, 2008 in Las Vegas, Nevada. PAREXEL is an Associate Sponsor of the conference.

PAREXEL experts will present in the following sessions, which address the implementation of metrics to enhance partnership performance, and strategies to successfully leverage emerging markets for global clinical trials:

Monday, April 14

Implementing Performance Metrics to Drive Time, Cost and Quality, and

Enhance Partnership Performance (workshop)

Kate Trainor, Vice President of Integration Services, Perceptive

Informatics, PAREXEL

(9:30 a.m. MT)

Tuesday, April 15

Outsourcing Clinical Trials in Emerging Regions: China

Karen Chu, Executive Director of International Clinical Operations,

PAREXEL APEX

(2:00 p.m. MT)

For more than 25 years, clients worldwide have relied on PAREXEL to provide integrated clinical development, regulatory affairs consulting, and commercialization services, as well as technologies that expedite time-to-market. Attendees at the 17th Annual Partnerships with CROs conference can visit with PAREXEL's Booth #123 in the exhibit hall to discuss these capabilities.

Visitors to PAREXEL's booth will receive a copy of the article "Create a Successful Project Plan for Global Clinical Trials," recently published in Applied Clinical Trials, by Diego Glancszpigel, Vice President of Clinical Operations for Latin America and Graciela Racaro, Senior Director of Clinical Operations for Latin America at PAREXEL.

For more information about PAREXEL visit http://www.PAREXEL.com or Booth #123 at the 17th Annual Partnerships with CROs conference.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has more than 7,300 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and PERCEPTIVE INFORMATICS is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird, Senior Director of Public Relations

PAREXEL International

Tel: +781-434-4409

Email: Jennifer.Baird@PAREXEL.com

Rebecca Passo

SHIFT Communications

Tel: +617-681-1817

Email: rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
2. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
3. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
4. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
5. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
6. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
7. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
8. PAREXEL International Announces 2-For-1 Stock Split
9. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
10. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
11. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 2017 , ... AxioMed will be presenting its viscoelastic cervical ... Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting the benefits ... the simplicity of the surgical technique,” said Jake Lubinski, President of AxioMed. ...
(Date:1/21/2017)... ... 20, 2017 , ... G&L Scientific Inc, a leading provider ... ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening and ... This is the latest step in G&L’s expansion of its global clinical consulting ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... our ongoing endeavors to bring to market a pioneering medical device for the ... has signed an engagement contract with Emergo, a global regulatory consultancy that helps ...
(Date:1/21/2017)... BOULDER, Colo. , Jan. 20, 2017 ... ("Bioptix" or the "Company"), announced that on January 14, ... a plan under which the Company will terminate certain ... subsidiary, Bioptix Diagnostics, Inc.  The Company commenced terminations on ... completed within 30 days.  The Company may pay severance ...
Breaking Biology Technology:
(Date:1/11/2017)... 11, 2017 Intoxalock, a leading ignition interlock ... of its patent-pending calibration device. With this new technology, ... securely upload data logs and process repairs at service ... "Fighting drunk driving through the application of cutting-edge ... large, but also for the customer who can get ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
Breaking Biology News(10 mins):